Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference
SOUTH SAN FRANCISCO, Calif., June 25, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced its participation at the upcoming 2025 A-T Clinical Research Conference organized by the A-T Society, a leading Ataxia-Telangiectasia (A-T) patient advocacy group based in the United Kingdom. Taking place June 25-27, 2025 at Loughborough University in the U.K., key opinion leaders (KOLs) will present post hoc data analyses from the company's prior Phase 3 ATTeST clinical trial of its lead asset, eDSP, for the treatment of patients with A-T. Additionally, Quince management will provide an overview of its pivotal Phase 3 NEAT clinical trial.
Highlights of A-T Clinical Research Conference Presentations
KOLs will present the following data and information at the upcoming A-T Clinical Research Conference:
Endocrine and Metabolic Events in Patients with A-T Treated with eDSP: William Whitehouse, M.D., Honorary Clinical Associate Professor of the School of Medicine at the University of Nottingham, England, recently retired Consultant Pediatric Neurologist at Nottingham Children's Hospital, Nottingham University Hospitals NHS Trust, and current Quince Scientific Advisory Board member, will provide a presentation titled Endocrine and Metabolic Events in Children with Ataxia-Telangiectasia Treated Long-term with Erythrocyte-Delivered Encapsulated Dexamethasone Sodium Phosphate (eDSP). The objective of the data analysis was to evaluate metabolic and endocrine adverse events (AEs), growth, and safety laboratory results in patients with A-T treated with eDSP. Key findings reported in Dr. Whitehouse's presentation highlighted that there were no reports of serious metabolic or endocrine events in the 68 patients with A-T treated with eDSP for two years or longer. Growth in height of these patients was also preserved.
MiniATM Family Expression in Patients with A-T Treated with eDSP: Michele Menotta, Ph.D., Associate Professor in the Department of Biomolecular Sciences at the University of Urbino in Urbino, Italy, will provide a presentation titled MiniATM Family Expression in ATTeST: Molecular Insights into Unusual ATM Variants in A-T Cells. The objective of the data analysis investigates the potential relationship between miniATM family expression in the blood of patients with A-T who participated in Quince's prior Phase 3 ATTeST clinical trial and their corresponding neurological scores. Additionally, novel functions of the miniATM family were explored in A-T cells and its molecular mechanism of action was investigated. The analysis found that miniATM genes were present in 40% of patients with A-T and were correlated with A-T disease severity at baseline. Lab tests also showed results that may variably influence cell processes, offering new insights for potential treatments.
Pivotal Phase 3 NEAT Enrollment Update
Quince's management will provide an overview of the company's pivotal Phase 3 NEAT (Neurologic Effects of eDSP on Subjects with A-T; #IEDAT-04-2022/NCT06193200) clinical trial and latest enrollment update at the A-T Society meeting. A total of 99 participants have been enrolled to date, including 78 participants in the six to nine year-old primary analysis population and 21 participants aged 10 years or older. All 42 NEAT participants to date have elected to transition to the NEAT open label extension (OLE) study (NCT06664853/IEDAT-04-2022).
Quince is currently enrolling a pivotal Phase 3 NEAT clinical trial, which is an international, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the neurological effects of eDSP (previously referred to as EryDex) treatment in patients with A-T. The company expects to report topline results in the first quarter of 2026 with a potential New Drug Application (NDA) submission to the FDA in the second half of 2026, assuming positive study results. Quince was granted Fast Track designation by the FDA for the company's eDSP System for the treatment of patients with A-T based on the potential for eDSP to address a high unmet medical need.
About Ataxia-Telangiectasia
A-T is an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene, which is responsible for cell homeostatic and cell division functions including but not limited to double-stranded DNA repair. Typically, A-T is first diagnosed before the age of five as children begin to develop an altered gait and fall with greater frequency. Neurological symptoms worsen and patients with A-T frequently become wheelchair-bound by adolescence. Teenage years for patients with A-T are typically marked by repeated infections, pulmonary impairment, and malignancies. The median lifespan is approximately 25 to 30 years old with mortality due to infections and malignancy. Based on IQVIA Medical Claims (Dx), PharmetricsPlus (P+), and IQVIA Analytics information, there are approximately 4,600 diagnosed patients with A-T in the U.S. Quince estimates that there are approximately 5,000 patients with A-T in the U.K. and EU4 countries. There are currently no approved therapeutic treatments in any global market for A-T.
About eDSP for A-T
eDSP is comprised of dexamethasone sodium phosphate (DSP) encapsulated in a patient's own red blood cells (autologous erythrocytes). DSP is a corticosteroid well known for its anti-inflammatory properties as well as its dose-limiting toxicity due to adrenal suppression. The eDSP System is designed to provide the efficacy of corticosteroids and to reduce or eliminate the significant adverse effects that accompany chronic use of corticosteroid treatment.
eDSP leverages Quince's proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells. Red blood cells have several characteristics that make them a potentially effective vehicle for drug delivery, including potentially better tolerability, enhanced tissue distribution, reduced immunogenicity, and prolongation of circulating half-life. Quince's AIDE technology is designed to harness these benefits to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response.
About Quince Therapeutics
Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince on social media platforms LinkedIn, Facebook, X, and YouTube.
Forward-looking Statements
Statements in this news release contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements contained in this news release may be identified by the use of words such as "believe," "may," "should," "expect," "anticipate," "plan," "believe," "estimated," "potential," "intend," "will," "can," "seek," or other similar words. Examples of forward-looking statements include, among others, statements relating to the timing, success, and reporting of results of the clinical trials and related data, including plans and the ability to enroll participants, impact of closing enrollment, conduct, and/or complete current and additional studies; expected cash position and operating runway; ability to secure additional funding and financial support; current and future clinical development of eDSP, including for the potential treatment of Ataxia-Telangiectasia (A-T), Duchenne muscular dystrophy (DMD), and other potential indications; the strategic development path for eDSP; planned regulatory agency submissions and clinical trials and timeline, prospects, and milestone expectations; and the potential benefits of eDSP and the company's market opportunity. Forward-looking statements are based on Quince's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled "Risk Factors" in the company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 13, 2025, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince undertakes no duty to update such information except as required under applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250625603299/en/
Contacts
Media & Investor Contact: Stacy RoughanQuince Therapeutics, Inc.Vice President, Corporate Communications & Investor Relationsir@quincetx.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
'It makes no sense to say there was only one origin of Homo sapiens': How the evolutionary record of Asia is complicating what we know about our species
When you buy through links on our articles, Future and its syndication partners may earn a commission. The story of our ancient ancestors began in Africa millions of years ago. But there are considerable gaps between the first and current chapters of that tale, and some anthropologists are looking to Asia to fill in missing information about how humans evolved. "The genus Homo evolved in Africa," Sheela Athreya, a biological anthropologist at Texas A&M University, told Live Science. But as soon as Homo left the continent, "all bets are off because evolution is going to treat every population differently." One bet Athreya is investigating is the notion that there wasn't a single origin of our species, Homo sapiens. Rather, the ancestors of today's humans living in different geographic regions took different evolutionary paths, before eventually coalescing into the human tribe we know today. Once humans left Africa, "you have so much complexity that it makes no sense to say there was only one origin of Homo sapiens," Athreya said. Key to this story is a different understanding of human evolution in Asia — and the possibility that Denisovans, a group of little-understood extinct human ancestors known from just a handful of fossils, were actually the same as a much earlier member of our family tree: Homo erectus, Athreya argues. Related: Strange, 300,000-year-old jawbone unearthed in China may come from vanished human lineage Early humans in ancient Asia There's a big gap in human evolutionary history. We know Homo evolved in Africa and that a human ancestor, Homo erectus, was already in Asia and parts of Europe by about 1.8 million years ago. But what happened in Asia between that point and the time when Homo sapiens arrived around 50,000 years ago? That picture is much less clear. To help fill it in, Athreya has considered the emergence of our species, Homo sapiens, during the Middle and Late Pleistocene epoch (780,000 to 11,700 years ago). Her "deep-dive" into the human fossil record of Asia has convinced her that there are evolutionary pathways in places like Java, Indonesia, that differ from the Pleistocene patterns seen in Africa and Europe. H. erectus reached Java at least 1.5 million years ago, and the species likely lasted there until 108,000 years ago. But the lack of more recent H. erectus bones doesn't necessarily mean they went extinct, Athreya wrote in a 2024 study with co-author Yousuke Kaifu, an anthropologist at the University of Tokyo. Instead, these Javanese H. erectus could have persisted until H. sapiens appeared in Sumatra as early as 73,000 years ago and interbred with them. The fossil record in China is similarly complicated. Around 300,000 years ago, there was a shift in what H. erectus fossils looked like, Athreya said. Skeletons in the Middle Pleistocene in China became more variable in form, and traits that were common in Western Eurasian groups like H. sapiens and Neanderthals, such as smoother bicuspid teeth, began to appear in these fossils. This means that — instead of completely dying out — H. erectus in China may have made a genetic contribution to populations living today, Athreya said, just as Neanderthals left genetic traces in people with European ancestry and Denisovans contributed DNA to people with Oceania ancestry. The idea isn't impossible, one expert told Live Science. Groups of ancient human relatives could have mated anywhere they met up, Adam Van Arsdale, a biological anthropologist at Wellesley College in Massachusetts, told Live Science. No matter where they lived, "I just think humans aren't that different" during the Pleistocene. What's more, anthropologists are starting to realize that many of these groups that looked very different could still have interbred. Twenty years ago, scientists would have said "there's no possible way" they could have interbred, Van Arsdale said. "And I just don't think we can assume that anymore." So far, no DNA has been recovered from H. erectus fossils, largely because most of their fossils are too old, so there's no genetic support for this idea. But emerging methods for extracting ancient proteins from fossils may soon make it feasible to identify some H. erectus genes. Another route to understanding the fate of H. erectus in Asia may be to look more closely at the enigmatic Denisovans. RELATED STORIES —Oldest wooden tools unearthed in East Asia show that ancient humans made planned trips to dig up edible plants —Ancient jawbone dredged off Taiwan seafloor belongs to mysterious Denisovan, study finds —140,000 year old bones of our ancient ancestors found on sea floor, revealing secrets of extinct human species Since the only known skull of a Denisovan looks similar, in many ways, to that of H. erectus, those two groups may actually be one and the same. "I don't think that genetics is going to find that Homo erectus was a separate dead-end lineage," Athreya said. "I would expect Denisovans to be Homo erectus." But until more work is done that combines DNA, artifacts and fossil bones in Southeast Asia, the full picture of human evolution cannot yet come into focus the way it has in places like Europe, Athreya said. Human evolution quiz: What do you know about Homo sapiens?
Yahoo
8 hours ago
- Yahoo
Trump, 79, Puts Cankles on Full Display as He Meets Putin
President Donald Trump's swollen ankles have made an appearance for the first time in weeks during his high-stakes summit with Russian counterpart Vladimir Putin, prompting renewed questions about his health. After greeting Putin in Alaska on Friday and giving him the red carpet treatment, the two leaders sat down for their first face-to-face meeting in years, as the American president sought to find an end to the war in Ukraine. But photos taken at the summit showed Trump's ankles looking somewhat enlarged again, weeks after the White House revealed he had been diagnosed with chronic venous insufficiency. CVI is a common condition in people over the age of 70, in which the veins of a person's body have trouble returning blood to the heart. While the condition isn't life-threatening, doctors say it gets riskier with age and can be exacerbated by a poor diet. Trump's health was subject to scrutiny in the days leading up to the summit, with reporters asking White House press secretary Karoline Leavitt for an update earlier this week. 'Look, you see the president every day,' she told reporters Tuesday. 'He's moving, he's working, he's continuing, there have been no adjustments made to his lifestyle.' But on Friday, a spokeswoman declined to answer questions about the president's health in view of the latest images, other than to refer the Daily Beast to Leavitt's earlier comments. The White House was also non-committal when CBS reporter Ed O'Keefe asked on Tuesday if Trump's White House physician Sean Barbabella could be made available to answer questions about the president's health. Similar requests have previously been made by the Daily Beast, but the White House did not oblige, and efforts to reach Barbabella's office directly were also unanswered. 'I don't want to make that commitment on behalf of the physician,' Leavitt told reporters on Tuesday. 'It's certainly something we can look into and explore out of the effort of transparency, because unlike the previous White House, there is nothing to hide.' Friday's summit was a critical juncture for Trump, who came to office promising to end the war in Ukraine 'on day one' of his presidency. Since then, however, his patience with Putin has been wearing thin as the Russian authoritarian continued to drag his heels on a ceasefire. 'We get a lot of bulls--t thrown at us by Putin, if you want to know the truth,' Trump said in June. 'He's very nice all the time but it turns out to be meaningless.' Despite the president's earlier concerns, the pair met for three hours in Alaska on Friday afternoon in the hope of a breakthrough. Secretary of State Marco Rubio and Special Envoy Steve Witkoff also joined Trump for the meeting, while Putin was accompanied by Russian Foreign Minister Sergei Lavrov and foreign policy adviser Yuri Ushakov. However, it is still not clear what exactly the meeting achieved in terms of a peace deal, given Putin's obsession with claiming Ukraine as his own and his ongoing reluctance to negotiate for a ceasefire.
Time Business News
18 hours ago
- Time Business News
Next-Gen Bioremediation Technologies Revolutionize Environmental Cleanup
Bioremediation is the process of using living organisms, such as germs, fungi, or plants, to make the environment clean and safe, to break or neutralize pollutants from soil, water and air. The bioremediation market is increasing due to increasing environmental concerns, strict government rules on pollution control, increasing industrial waste and demand for environmentally friendly and cost -effective cleaning methods. Increased awareness about progress and sustainable practices in biotechnology is moving forward in areas such as oil and gas, agriculture and waste water treatment. Key Growth Drivers and Opportunities Increasing Environmental Concerns: Increasing environmental concerns are driving the growth of the bioremediation market as governments, industries, and communities seek sustainable and eco-friendly solutions to combat pollution. With increasing awareness about industrial waste, oil spread, and contaminated soil and harmful effects of water, the demand for natural and less aggressive cleaning methods is increasing. Bioremediation provides an effective, cost-efficient and environmentally safe option for traditional therapeutic techniques, causing widespread adoption and market expansion in areas. Challenges The bioremediation market faces limitations such as microbial or slow speed of plant-based cleanup processes, which may not be suitable for emergency or large-scale contamination. Effectiveness may be unexpectedly due to the presence of toxins that disrupt microbial activity such as temperature, pH, and toxins. Additionally, bioremediation is often limited to specific types of pollutants and may require a wider site monitoring. Using genetically modified organisms (GMOs) can cause regulatory approval and widely adopting public skepticism. Innovation and Expansion The New Glyphosate Bioremediation Solution Revealed by Ancient Organics In May 2023, PaleoPower will go on sale, according to Ancient Organics Bioscience, Inc., an agricultural technology firm that creates its own line of plant and soil probiotics. The only substance that is known to decompose glyphosate contamination in soil naturally is PaleoPower. A group of helpful microbes called PaleoPower breaks down glyphosate. The active component of Roundup and other popular glyphosate-based herbicides is glyphosate. PaleoPower decreased soil glyphosate levels by more than 80% during 90 days of treatment and by more than 90% within 180 days of application in controlled tests. An Innovative Approach to Address Acid Mine Drainage in Northeast Coal Mines IIT Guwahati Develops In June 2022, The Indian Institute of Technology Guwahati A study on the 'bioremediation' of Acid Mine Drainage (AMD) in Constructed Wetlands has been conducted by researchers using coal mines. This is the first research to show how constructed wetlands may be used to bioremediate AMD from the Northeastern Coalfields (NEC). The term 'acid mine drainage' describes the acidic wastewater produced by coal mines (or any polymetallic mine) that contains significant levels of iron, sulfate, and other hazardous heavy metals. This study addresses the long-term operational sustainability concerns that arise in constructed wetlands that receive AMD while offering an effective sustainable treatment method to reduce AMD contamination. To further comprehend the operation of several basic processes that co-occur in constructed wetlands, a biochemical mechanism has been established. Inventive Sparks, Expanding Markets Major development strategies for bioremediation companies include investing in advanced microbial and genetic technologies, expanding applications in industries such as agriculture, oil and gas and waste water, forming partnership with environmental agencies and focusing on permanent, low -cost solutions. Companies aim to increase operations through government cooperations and regulatory approval by increasing R&D for targeted and rapid therapeutic methods. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
